← All trials
NCT04411433
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 8, 2020
- Primary completion
- Jul 30, 2020
- Completion date
- Jul 30, 2020
- First posted
- Jun 2, 2020
- Last posted
- Jun 2, 2020
- Enrollment
- 1000
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Government of TurkeyLead sponsor
- Istanbul UniversityCollaborator
- University of AnkaraCollaborator
- Hacettepe UniversityReponsible party - principal investigator
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyCollaborator
- Kocaeli UniversityCollaborator
- Ankara Yildirim Beyazıt UniversityCollaborator
- Ege UniversityCollaborator
- Hacettepe UniversityCollaborator
- Istanbul UniversityCollaborator
- Kayseri City HospitalCollaborator
- Prof. Dr. Cemil Tascıoglu Education and Research Hospital OrganizationCollaborator
- SB Istanbul Education and Research HospitalCollaborator
- Tepecik Education and Research HospitalCollaborator
- Umraniye Education and Research HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.